Alcon commercially launches Tryptyr (acoltremon ophthalmic solution) 0.003% for signs and symptoms of DED in the US
The solution was approved by the US Food and Drug Administration in late May 2025.
The first-in-class TRPM8 receptor agonist (neuromodulator) was approved by the FDA based on 2 phase 3 clinical trials. Image credit: AdobeStock/megaflopp
Alcon recently announced the US commercial availability of Tryptyr (acoltremon ophthalmic solution) 0.003% for the treatment of the signs and symptoms of dry eye disease (DED), according to a news release.1 The solution was approved by the US Food and Drug Administration in late May 2025 and is packaged in single-dose vials to be administered as 1 drop per eye twice a day.1,2
“TRYPTYR is highly anticipated in the Dry Eye Disease treatment space as the first neuromodulator eye drop to rapidly increase natural tear production, as early as day one,” said Lisa Praeger, Vice President, General Manager, U.S. Ocular Health Pharmaceutical, Alcon. “As the global eye care leader with a comprehensive portfolio of dry eye products—from over-the-counter offerings to prescription therapies—Alcon is uniquely positioned to deliver this innovation to Eye Care Professionals and the millions of patients who need Dry Eye Disease relief. Leveraging our deep commercial expertise and specialized sales force, we’re excited to give broader access to this important new treatment option.”
The first-in-class TRPM8 receptor agonist (neuromodulator) was approved by the FDA based on 2 phase 3 clinical trials, COMET-2 and COMET-3, which demonstrated a statistically significant increase in natural tear production as early as Day 1. In the trials, 4 times more Tryptyr patients experienced at least a 10-mm increase in natural tear production at day 14 when compared to vehicle.2
The neuromodulator in the solution stimulates corneal sensory nerves in order to increase natural tear production rapidly following instillation.2
“Understanding patients’ dry eye disease struggles allow us to make informed
recommendations on how to best manage their symptoms and create an effective ongoing disease management plan,” said Paul Karpecki, OD, director of Corneal Services and the Advanced OSD Clinic in Lexington, Kentucky, in the release. “Tryptyr represents an important innovation—its fast onset and novel mechanism provide a new option to millions of dry eye patients.”
Alcon has also launched an eye care provider campaign with its team of dry eye sales specialists that focuses on the speed of rapid natural tear production with Tryptyr. The campaign includes tools for providers, including videos and an interactive website, in addition to a patient website.1
“TRYPTYR is an important milestone in the treatment of Dry Eye Disease, and I’m equally encouraged by Alcon’s commitment to supporting eye care as we continue to address the signs and symptoms of Dry Eye Disease for our patients,” said Preeya K. Gupta, MD, Triangle Eye Consultants in Raleigh, North Carolina. "Alcon is not only expanding the dry eye treatment options, but they are also supporting clinicians with the educational resources needed to confidently integrate new treatments like TRYPTYR into our practices.”
The launch also coincides with expansive access initiatives, including a full Field Access Management team that will be dedicated to assisting eye care providers with fulfillment and a First Fill Free trial program for eligible Tryptyr patients. Ongoing copay support will also be offered for refills for eligible patients.1
References:
Alcon announces US launch of Tryptyr (acoltremon ophthalmic solution) 0.003%, a new prescription treatment option for millions of dry eye sufferers. News release. Alcon. July 29, 2025. Accessed July 31, 2025. https://investor.alcon.com/news-and-events/press-releases/news-details/2025/Alcon-Announces-U-S--Launch-of-TRYPTYR-acoltremon-ophthalmic-solution-0-003-a-New-Prescription-Treatment-Option-for-Millions-of-Dry-Eye-Sufferers--2025-lTxhuYLMsa/default.aspx
Maharjan EK, Harp MD. FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease. Optometry Times. May 29, 2025. Accessed July 31, 2025. https://www.optometrytimes.com/view/fda-approves-alcon-s-tryptyr-ar-15512-for-signs-and-symptoms-of-dry-eye-disease
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
